Riccardo Mei
Papers
1
Total Citations
6
H-Index
1
About
Riccardo Mei is a rising figure in urologic oncology, whose work centers on refining the use of molecular imaging for prostate cancer management. His primary research focus lies at the intersection of histopathology and nuclear medicine, particularly in optimizing patient selection for PSMA-PET imaging. In his most cited work, Mei conducted a critical immunohistochemistry analysis of PSMA expression in high-risk prostate cancer biopsy specimens, directly correlating tissue-level protein expression with potential imaging outcomes. This study, which has already garnered 6 citations since its 2024 publication, provides essential evidence for why some patients may show false-negative PSMA-PET results, thereby improving the clinical utility of this powerful staging tool. By bridging the gap between pathology and radiology, Mei’s contributions help clinicians better identify which high-risk patients will truly benefit from PSMA-targeted therapies and imaging. His work represents a significant step toward more personalized, biomarker-driven decision-making in prostate cancer care, offering a practical framework for integrating molecular pathology with advanced imaging protocols.
Research Focus
Key Achievements
Top Papers
- 1